Hybrid Molecular Sensing Technology
Our technology integrates nanobiosensors with advanced machine‑learning algorithms to achieve ultra‑sensitive detection.
–AI‑Driven Analysis: Deep‑learning models interpret molecular signals with unmatched accuracy.
–Real‑Time Feedback: Instant results for rapid clinical decision‑making.
HMSense introduces a new generation of molecular diagnostics built on a hybrid sensing principle that merges biological precision with intelligent signal interpretation. Our platform is designed to deliver rapid, reliable, and accessible biomarker detection empowering clinicians and laboratories with actionable insights in minutes.
Our technology is built upon a novel visual nano‑biosensor capable of detecting multiple cancer biomarkers simultaneously using unamplified cell‑free nucleobiomarkers. This approach eliminates the need for PCR amplification, enabling rapid, low‑cost, and highly sensitive molecular diagnostics. It demonstrates the potential of nano‑genosensing for early‑phase cancer detection focusing on identifying subtle molecular signals in biofluids such as plasma, enabling non‑invasive diagnostics that support precision medicine.
Core Scientific Principles
Our technology translates these scientific insights into a practical diagnostic system that detects molecular biomarkers rapidly and visually. It leverages the principles of optical signal modulation and biomarker‑specific recognition, allowing clinicians to interpret results in real time.
–Nano‑biosensor design: The platform uses engineered functionalized nanoparticles that selectively bind to nucleobiomarkers associated with prevalent cancers.
–Colorimetric signal generation: Hybridization between target biomarker and functionalized nanoparticles induces a measurable color change, allowing visual or spectrophotometric detection without complex instrumentation.
–Simultaneous multi‑cancer detection: The biosensor is optimized to detect common biomarkers supporting early screening for cancers such as breast, lung, colorectal, and prostate.
–Unamplified detection: By removing amplification steps, the system reduces cost, complexity, and turnaround time while maintaining high analytical sensitivity.
Clinical Impact
This nano‑biosensor platform provides a powerful alternative to conventional molecular diagnostics by enabling fast, accessible, and multiplex cancer detection, ideal for early screening programs, resource‑limited settings, and decentralized healthcare environments.
–Early detection: Identifies molecular changes before clinical symptoms appear.
–Non‑invasive sampling: Uses plasma or serum instead of tissue biopsies.
–Rapid interpretation: Provides visual differentiation within seconds.
–Scalable design: Adaptable for multiple cancer types and screening programs.
The underlying scientific framework has been validated in clinical studies involving diverse cancer types including breast, colon, lung, and stomach demonstrating strong correlation between molecular signal intensity and disease stage.
دیدگاهتان را بنویسید